Cas:914221-44-6 4-(4-butylcyclohexyl)cyclohexan-1-one manufacturer & supplier

Chemical Name:4-(4-butylcyclohexyl)cyclohexan-1-one

CAS.NO:914221-44-6

Synonyms:4′-Butylbi(cyclohexyl)-4-one

Molecular Formula:C₁₆H₂₈O

Molecular Weight:236.39300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:0.931

Index of Refraction:

PSA:17.07000

Exact Mass:236.21400

LogP:4.74230

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4′-Butylbi(cyclohexyl)-4-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4′-Butylbi(cyclohexyl)-4-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4′-Butylbi(cyclohexyl)-4-one Use and application,4′-Butylbi(cyclohexyl)-4-one technical grade,usp/ep/jp grade.

Related News: As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 4-(4-butylcyclohexyl)cyclohexan-1-one manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 4-(4-butylcyclohexyl)cyclohexan-1-one supplier CROS NT built up its own biometric services portfolio: clinical data management, biostatistics, statistical programming and medical writing, through a series of acquisitions in the early 2010s. In 2013, CROS NT established a foothold in the U.S. with its purchase of Stat-Tech Services, which had a presence in the medical devices sector. CROS NT followed up the next year with its buy of biometrics services provider MDSL International to broaden its U.K. branch. 4-(4-butylcyclohexyl)cyclohexan-1-one vendor As many as 9,000 medical workers in Hong Kong have pledged to strike this week, a threat that alarms the territory��s officials as they are struggling to contain the coronavirus outbreak. 4-(4-butylcyclohexyl)cyclohexan-1-one factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.